Clinical Trial Update: Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer [NA]

View source ↗

Summary

This clinical trial evaluates whether Cu-64-DOTA-Trastuzumab PET imaging can predict response to ado-trastuzumab emtansine in metastatic HER2-positive breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ado-Trastuzumab Emtansine (ado-trastuzumab emtansine)
• Cu-64-DOTA-Trastuzumab (Copper-64 DOTA-Trastuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Bone Metastases, HER2-positive Breast Cancer | NA | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-07-20